J&J, FDA leaders take heat for ‘phantom’ recall

Question of the Day

Is it still considered bad form to talk politics during a social gathering?

View results

WASHINGTON (AP) - Johnson & Johnson executives and the Food and Drug Administration both shouldered the blame Thursday for a secret recall in which hired contractors quietly bought up defective painkillers to clear them from store shelves.

J&J Chief Executive William Weldon told House lawmakers the company “made a mistake” in conducting the so-called “phantom recall,” which is one of a string of problems that have drawn congressional scrutiny

In the same committee hearing, the FDA’s deputy commissioner, Dr. Joshua Sharfstein, said his agency should have acted sooner to halt J&J’s plan. At the same time, though, he stressed that regulators were not aware of the deceptive nature of the recall.

Sharfstein and Weldon testified before the House Committee on Oversight and Government Reform, which held its second hearing on J&J’s unprecedented spate of recalls. The largest, involving more than 135 million bottles of infants’ and children’s Tylenol and other medicines, triggered the committee’s investigation.

“We recognize that we need to do better, and we will work hard to restore the public’s trust and faith in Johnson & Johnson,” Weldon told lawmakers.

Democrats and Republicans pressed Weldon on its “phantom” recall involving 88,000 packets of Motrin, which Weldon acknowledged as “not one of our finer moments.”

But lawmakers also pressed the FDA on when and what it knew about the activity. New Brunswick, N.J.-based J&J has repeatedly claimed it alerted the agency’s officials in Puerto Rico, where the defective Motrin was originally manufactured.

Sharfstein said J&J informed the FDA of its plan to repurchase the pills _ which did not dissolve correctly _ in April 2009.

“From this point, it took until July for the FDA to tell the company that a recall should be conducted,” Sharfstein said in his testimony. “In my opinion that message should have been given sooner.”

But Sharfstein stressed that the FDA did not know J&J had instructed contractors to pose as regular customers while buying the product and to not alert store employees to their activity.

“Based on the documents I reviewed, I don’t see any indication that the FDA was aware of the surreptitious, lying nature of the recall,” he said.

Republican lawmakers criticized a “too cozy” relationship between FDA and J&J employees, citing months-long e-mail exchanges between the two before regulators took action. But Sharfstein said ultimate blame lies with J&J, pointing out that the FDA does not have the authority to order when and how companies conduct recalls.

“I think fundamentally the responsibility is with the company to handle their quality problems in a much different way,” Sharfstein said.

Companies are advised to work with the FDA on recalls, although that isn’t a legal requirement.

Committee Chairman Edolphus Towns, D-N.Y., has introduced a bill that would give the agency the power to order recalls.

Story Continues →

View Entire Story

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Comments
blog comments powered by Disqus
TWT Video Picks